BACKGROUND: Clinicopathologic stage is still the main parameter to evaluate the prognosis of newly diagnosed colorectal cancer (CRC) patients. Although molecular markers have been suggested for follow up of treated CRC patients, their complete clinical application is still under evaluation. MATERIALS AND METHODS: To evaluate the association of immune-related genes with CRC prognosis and survival, a total of 19 single nucleotide polymorphisms (SNPs) were genotyped in 614 German patients within the Kiel cohort (POPGEN). RESULTS: A promoter variant (rs1800872) in the Interleukin-10 (IL-10) gene was associated with an increased lymph node metastasis involvement [odds ratio (OR) = 2.1, 95% confidence interval (CI) = 1.03-4.2, for carriers of the TT genotype]. More importantly, among 582 followed up patients the SNP rs3775291 in the toll-like receptor 3 (TLR-3) gene was associated with CRC specific survival (150 events). Patients carrying the TT genotype had a 93% increased risk of death compared with the CC carriers [hazard ratio (HR) = 1.93, 95% CI 1.14-3.28]. The observed effect of the TLR-3 variant was restricted to stage II patients (HR = 4.14, 95% CI 1.24-13.84) and to patients who did not receive adjuvant therapy (HR = 3.2, 95% CI 1.4-7.7). CONCLUSIONS: Our results may provide additional candidates for risk assessment in stage II CRC patients for treatment decision. Further validation of the presented findings is warranted.
BACKGROUND: Clinicopathologic stage is still the main parameter to evaluate the prognosis of newly diagnosed colorectal cancer (CRC) patients. Although molecular markers have been suggested for follow up of treated CRC patients, their complete clinical application is still under evaluation. MATERIALS AND METHODS: To evaluate the association of immune-related genes with CRC prognosis and survival, a total of 19 single nucleotide polymorphisms (SNPs) were genotyped in 614 German patients within the Kiel cohort (POPGEN). RESULTS: A promoter variant (rs1800872) in the Interleukin-10 (IL-10) gene was associated with an increased lymph node metastasis involvement [odds ratio (OR) = 2.1, 95% confidence interval (CI) = 1.03-4.2, for carriers of the TT genotype]. More importantly, among 582 followed up patients the SNP rs3775291 in the toll-like receptor 3 (TLR-3) gene was associated with CRC specific survival (150 events). Patients carrying the TT genotype had a 93% increased risk of death compared with the CC carriers [hazard ratio (HR) = 1.93, 95% CI 1.14-3.28]. The observed effect of the TLR-3 variant was restricted to stage II patients (HR = 4.14, 95% CI 1.24-13.84) and to patients who did not receive adjuvant therapy (HR = 3.2, 95% CI 1.4-7.7). CONCLUSIONS: Our results may provide additional candidates for risk assessment in stage II CRC patients for treatment decision. Further validation of the presented findings is warranted.
Authors: Noemi Eiro; Juan Francisco Carrión; Sandra Cid; Alejandro Andicoechea; José Luis García-Muñiz; Luis O González; Francisco J Vizoso Journal: Pathol Oncol Res Date: 2019-02-01 Impact factor: 3.201
Authors: Hui Wang; Sinead M Flannery; Sabine Dickhöfer; Stefanie Huhn; Julie George; Andriy V Kubarenko; Jesus Lascorz; Melanie Bevier; Joschka Willemsen; Tica Pichulik; Clemens Schafmayer; Marco Binder; Bénédicte Manoury; Søren R Paludan; Marta Alarcon-Riquelme; Andrew G Bowie; Asta Försti; Alexander N R Weber Journal: J Biol Chem Date: 2014-06-19 Impact factor: 5.157
Authors: Jesús Lascorz; Melanie Bevier; Witigo V Schönfels; Holger Kalthoff; Heiko Aselmann; Jan Beckmann; Jan Egberts; Stephan Buch; Thomas Becker; Stefan Schreiber; Jochen Hampe; Kari Hemminki; Clemens Schafmayer; Asta Försti Journal: Int J Colorectal Dis Date: 2012-07-28 Impact factor: 2.571
Authors: Hansong Wang; Darin Taverna; Daniel O Stram; Barbara K Fortini; Iona Cheng; Lynne R Wilkens; Terrilea Burnett; Karen W Makar; Noralane M Lindor; John L Hopper; Steve Gallinger; John A Baron; Robert Haile; Laurence N Kolonel; Brian E Henderson; Polly A Newcomb; Graham Casey; David Duggan; Cornelia M Ulrich; Loïc Le Marchand Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-09-17 Impact factor: 4.254